Arrowhead Pharmaceuticals, Inc.
ARWR
$21.33
$0.582.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2,816.21% | 1,436.97% | -98.62% | -98.52% | -92.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,816.21% | 1,436.97% | -98.62% | -98.52% | -92.33% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 2,816.21% | 1,436.97% | -98.62% | -98.52% | -92.33% |
| SG&A Expenses | 14.65% | 11.26% | 12.58% | 13.79% | 2.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.13% | 30.34% | 30.61% | 35.65% | 29.80% |
| Operating Income | 80.27% | 74.98% | -109.06% | -193.21% | -203.16% |
| Income Before Tax | 71.31% | 68.15% | -113.88% | -196.60% | -205.39% |
| Income Tax Expenses | 252.56% | 539.93% | 218.86% | -199.39% | -128.35% |
| Earnings from Continuing Operations | 70.89% | 67.61% | -114.48% | -191.34% | -197.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 25.27% | 59.26% | 62.98% | 155.00% | 182.00% |
| Net Income | 72.45% | 69.42% | -115.53% | -192.04% | -197.41% |
| EBIT | 80.27% | 74.98% | -109.06% | -193.21% | -203.16% |
| EBITDA | 83.88% | 78.72% | -112.51% | -202.58% | -213.09% |
| EPS Basic | 73.33% | 68.02% | -86.16% | -160.56% | -173.05% |
| Normalized Basic EPS | 74.56% | 69.43% | -86.20% | -166.00% | -181.06% |
| EPS Diluted | 72.73% | 67.22% | -85.99% | -160.32% | -172.72% |
| Normalized Diluted EPS | 74.05% | 68.88% | -85.80% | -165.16% | -180.05% |
| Average Basic Shares Outstanding | 12.88% | 13.90% | 15.94% | 12.24% | 8.56% |
| Average Diluted Shares Outstanding | 13.12% | 14.15% | 15.57% | 11.87% | 8.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |